[go: up one dir, main page]

MA35303B1 - Vaccin contre la rhinite equine - Google Patents

Vaccin contre la rhinite equine

Info

Publication number
MA35303B1
MA35303B1 MA36241A MA36241A MA35303B1 MA 35303 B1 MA35303 B1 MA 35303B1 MA 36241 A MA36241 A MA 36241A MA 36241 A MA36241 A MA 36241A MA 35303 B1 MA35303 B1 MA 35303B1
Authority
MA
Morocco
Prior art keywords
equine rhinitis
vaccine against
against equine
rhinitis
immunogenic compositions
Prior art date
Application number
MA36241A
Other languages
English (en)
Inventor
Laurent Viel
Andres Diaz-Mendez
Phillip Wayne Hayes
Kristina J Hennessy
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of MA35303B1 publication Critical patent/MA35303B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des compositions immunogènes contre le virus de la rhinite equine, en particulier les virus a et b de la rhinite equine, et des procédés pour leur utilisation et leur préparation. Les compositions immunogènes, dans d'autres modes de réalisation, comprennent également d'autres pathogènes équins.
MA36241A 2011-03-14 2013-09-12 Vaccin contre la rhinite equine MA35303B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21
PCT/US2012/028706 WO2012125525A2 (fr) 2011-03-14 2012-03-12 Vaccin contre la rhinite équine

Publications (1)

Publication Number Publication Date
MA35303B1 true MA35303B1 (fr) 2014-08-01

Family

ID=45876924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36241A MA35303B1 (fr) 2011-03-14 2013-09-12 Vaccin contre la rhinite equine

Country Status (12)

Country Link
US (1) US9187730B2 (fr)
EP (2) EP2686012B1 (fr)
AR (1) AR085800A1 (fr)
AU (2) AU2012229192B2 (fr)
BR (2) BR122019023542B1 (fr)
CA (2) CA3018230A1 (fr)
ES (2) ES2748555T3 (fr)
MA (1) MA35303B1 (fr)
MX (2) MX385188B (fr)
NZ (1) NZ614147A (fr)
TW (1) TW201300537A (fr)
WO (1) WO2012125525A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385188B (es) 2011-03-14 2025-03-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
US10555998B2 (en) 2014-11-24 2020-02-11 Intervet Inc. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
CN120771270A (zh) * 2017-12-04 2025-10-14 英特维特国际股份有限公司 具有复制子颗粒和油佐剂的疫苗

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
DE60233206D1 (de) 2001-02-28 2009-09-17 Intervet Int Bv Wasser-in-öl-injektionsemulsionen
CA2440593A1 (fr) 2001-03-12 2002-09-19 Yale University Procedes et compositions comprenant des polypeptides du virus west nile
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) * 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
DK1427444T3 (da) 2001-07-27 2013-11-04 Zoetis W Llc West-nil-vaccine
BR0213408A (pt) 2001-10-19 2004-11-03 Acambis Inc Métodos de prevenção e de tratamento de infecção por flavivìrus em animais
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
CA2432738A1 (fr) 2003-02-26 2004-08-26 Philippe Despres Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
EP1664786B1 (fr) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection de l'infection par le virus du nil occidental et vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
CA2582534A1 (fr) 2004-09-09 2006-03-16 Research Development Foundation Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes
EP1645283A1 (fr) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Composition de vaccin combiné
CA2591665C (fr) 2004-12-20 2015-05-05 Crucell Holland B.V. Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2007002470A2 (fr) 2005-06-24 2007-01-04 Intervet International B.V. Vaccins chimeres inactives et leurs procedes d'utilisation
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
RS20080138A (sr) 2005-10-07 2009-07-15 Pfizer Products Inc., Vakcine i metode lečenja influence kod canina
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US7601502B2 (en) 2005-11-01 2009-10-13 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
BRPI0918897B1 (pt) 2008-08-29 2021-06-15 Boehringer Ingelheim Animal Health USA Inc. Composição imunogênica e seus usos
MX385188B (es) 2011-03-14 2025-03-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.

Also Published As

Publication number Publication date
EP2686012A2 (fr) 2014-01-22
AR085800A1 (es) 2013-10-30
ES2842595T3 (es) 2021-07-14
AU2017201526A1 (en) 2017-03-30
WO2012125525A3 (fr) 2013-02-28
TW201300537A (zh) 2013-01-01
AU2012229192A1 (en) 2013-08-29
NZ614147A (en) 2015-08-28
CA3018230A1 (fr) 2012-09-20
AU2017201526B2 (en) 2019-07-18
MX2013010125A (es) 2013-10-07
BR112013023354A2 (pt) 2016-12-06
EP2772266B1 (fr) 2019-07-31
EP2686012B1 (fr) 2020-12-02
BR112013023354B1 (pt) 2022-02-15
WO2012125525A2 (fr) 2012-09-20
MX385188B (es) 2025-03-14
EP2772266A1 (fr) 2014-09-03
US20120237543A1 (en) 2012-09-20
CA2829226A1 (fr) 2012-09-20
ES2748555T3 (es) 2020-03-17
NZ708320A (en) 2016-08-26
MX350718B (es) 2017-09-14
US9187730B2 (en) 2015-11-17
BR122019023542B1 (pt) 2022-02-15
CA2829226C (fr) 2023-01-03
AU2017201526C1 (en) 2019-10-24
AU2012229192B2 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MA35414B1 (fr) Formulations de vaccin parenteral contre un norovirus
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
MX2010005356A (es) Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2012008221A (es) Inhibidores de virus flaviviridae.
GEP201706698B (en) Inhibitors of influenza viruses replication
MX2012008211A (es) Inhibidores de virus flaviviridae.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2012002925A (es) Inhibidores de virus flaviviridae.
IN2014MN01548A (fr)
MX349294B (es) Formulaciones virales liofilizadas.
MX373096B (es) Formulaciones virales líquidas.
EA201290956A1 (ru) Вакцина против вич
WO2011079073A3 (fr) Vaccins anti-virus herpès simplex
WO2010053610A3 (fr) Formulations stables de vaccin contre l'anthrax
WO2012047267A3 (fr) Immunogène polyvalent
MA35303B1 (fr) Vaccin contre la rhinite equine
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
WO2014167582A3 (fr) Composition de vaccin contre la prophylaxie chez des ruminants